This bill proposes the repeal of the Prescription Drug Affordability Board (PDAB) and related provisions in New Hampshire law. Specifically, it deletes the position of the executive director of the PDAB from the salary schedule in RSA 94:1-a, I(b) and repeals RSA 6:12, I(b)(384), which pertains to the PDAB administration fund, as well as RSA 126-BB, which outlines the board's functions. The effective date for this repeal is set for July 1, 2025.

Additionally, the bill includes a fiscal note indicating that it does not provide funding for the PDAB, with no expected revenue generated from this action. However, it does mention that expenditures related to the position of executive director, which was previously established for a two-year term, would have been approximately $140,000 in FY26, $148,000 in FY27, and $153,000 in FY28, funded by the state general fund. The bill effectively eliminates the board and its associated costs, streamlining the state's approach to prescription drug affordability.

Statutes affected:
Introduced: 126-BB:1, 126-BB:2
As Amended by the House: 94:1-a